Using Bioluminescence Imaging to Study Autoimmune Encephalomyelitis
Author Information
Author(s): Luo Jian, Ho Peggy, Steinman Lawrence, Wyss-Coray Tony
Primary Institution: Stanford University School of Medicine
Hypothesis
Can bioluminescence imaging predict disease severity in autoimmune encephalomyelitis?
Conclusion
Bioluminescence imaging can effectively monitor neuroinflammation and predict disease severity in autoimmune encephalomyelitis.
Supporting Evidence
- Bioluminescence correlates strongly with clinical scores and weight loss.
- Bioluminescence can predict peak clinical scores several days before symptoms appear.
- The study highlights the potential of bioluminescence imaging for rapid drug screening.
Takeaway
Scientists used special mice that glow to see how bad a disease is getting, helping them understand and treat it better.
Methodology
Transgenic mice were used to measure bioluminescence in the brain and spinal cord, correlating it with clinical disease severity.
Limitations
The correlation of GFAP increase with long-term neurological deficits is not well established.
Participant Demographics
Mice aged 8 to 12 weeks were used in the experiments.
Statistical Information
P-Value
< 0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website